Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 544 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resected Stage Clear all
Not listed Phase 2 Interventional

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

NCT01746251
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Afatinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 22, 2026, 5:34 AM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

NCT06072586
View directory record Official record
Conditions
High Grade Glioma, Glioblastoma
Interventions
BDTX-1535, BDTX-1535 combined with radiation therapy, BDTX-1535 combined with temozolomide and radiation therapy
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chandler, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Glioma Supra Marginal Incision Trial

NCT04737577
View directory record Official record
Conditions
High Grade Glioma
Interventions
Supramarginal resection, Conventional (i.e. GTR) resection
Procedure
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma

NCT00183911
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer
Interventions
floxuridine, 5-Fluorouracil, leucovorin, External Beam Radiotherapy, Surgery
Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

NCT00003484
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
carmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6
Drug · Procedure · Radiation
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 22, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

NCT03469258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancrelipase
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 22, 2026, 5:34 AM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 22, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

NCT02450331
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
41
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 22, 2026, 5:34 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis

NCT02452437
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Oxycodone
Drug
Lead sponsor
Emerio & Lourdes Linares Research and Education Center
Other
Eligibility
30 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 22, 2026, 5:34 AM EDT
Withdrawn Phase 2 Interventional

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

NCT01524575
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, ERCC1
Interventions
gemcitabine and oxaliplatin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers

NCT05120947
View directory record Official record
Conditions
Resectable Head and Neck Squamous Cell Carcinoma
Interventions
42 Gy Radiation Therapy, 39 Gy Radiation Therapy, 32.5 Gy Radiation Therapy
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 22, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional Results available

Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed

NCT00002525
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2015
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer

NCT01271738
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of Breast, Cancer of the Breast, Human Mammary Carcinoma, Neoplasms, Breast
Interventions
Remove tumor only, Removal of tumor and tissue
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

NCT00203892
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
modified CEA peptide (10mcg), modified CEA peptide (100mcg), modified CEA peptide (1000mcg)
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

NCT01682213
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 22, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

NCT01326923
View directory record Official record
Conditions
Head and Neck Squamous Cell Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Phase 3 Interventional

Conventional or Video-Assisted Surgery in Treating Patients With Lung Metastases

NCT00003724
View directory record Official record
Conditions
Metastatic Cancer
Interventions
surgical procedure
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
45
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Early Phase 1 Interventional

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

NCT00436410
View directory record Official record
Conditions
Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma
Interventions
colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study, conventional surgery
Biological · Other · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection

NCT00303654
View directory record Official record
Conditions
Bladder Cancer
Interventions
biopsy, therapeutic conventional surgery
Procedure
Lead sponsor
Roei Medical Technologies Ltd.
Industry
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 22, 2026, 5:34 AM EDT
Terminated Phase 1Phase 2 Interventional

Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery

NCT00410774
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, gemcitabine hydrochloride, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery

NCT00006470
View directory record Official record
Conditions
Lung Cancer
Interventions
monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, radiation therapy
Biological · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
218
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas

NCT00042991
View directory record Official record
Conditions
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligodendroglioma
Interventions
gefitinib, radiation therapy, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 22, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

NCT00242918
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, ZD1839
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 22, 2026, 5:34 AM EDT
Terminated Phase 1 Interventional

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

NCT02559024
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
MEDI6469
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 22, 2026, 5:34 AM EDT